Biotech Values

[DewDiligence]

…room to compete with...sofosbuvir-based regimens on price, particularly given the significant amount GILD needs to recoup from its acquisition of VRUS.

The money GILD spent to acquire Pharmasset won’t determine how Sofosbuvir is priced. Third-party payers will.